^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLN-619

    i
    Other names: CLN-619
    Associations

    News

    Trials
    Company:
    Cullinan Therap
    Drug class:
    γδ TCR modulator, MICA agonist, MICB agonist, NKG2D stimulant
    Related drugs:
    Associations

    News

    Trials
    26d
    A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-619
    2ms
    A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=410, Recruiting, Cullinan Oncology Inc. | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • CLN-619
    over1year
    A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=410, Recruiting, Cullinan Oncology, LLC | N=148 --> 410
    Enrollment change • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • CLN-619
    over1year
    CLN-619, a clinical-stage MICA/B-specific IgG1 antibody which restores the MICA/B-NKG2D axis requires Fc function for potent anti-tumor activity (SITC 2022)
    Treatment was administered 2X weekly for four weeks intraperitoneal. Statistics were analyzed by one-way ANOVA adjusted for multiple comparisons.
    Clinical
    |
    MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
    |
    CLN-619
    2years
    CLN-619, a clinical-stage MICA/MICB-specific IgG1 antibody, restores the MICA/MICB-NKG2D axis to promote NK-mediated tumor cell lysis (AACR 2022)
    Given the pan-cancer expression of MICA/MICB in both solid and hematological malignancies, CLN-619 is expected to have broad anti-tumor activity. CLN-619 is currently being investigated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors.
    Clinical
    |
    MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
    |
    CLN-619